# A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants

> **NCT07422207** · PHASE1 · RECRUITING · sponsor: **Meiji Pharma USA Inc.** · enrollment: 104 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** ME3241
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07422207
- **Lead sponsor:** Meiji Pharma USA Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07422207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07422207, "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07422207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*